Pharmacological SciencesAnticancer Drug Development
- Acknowledgements
- Administration Schedules
- Alemtuzumab
- Amplification
- Candidate Gene Approach
- Concluding Remarks
- Conclusion - 2
- Conclusions - 2
- Conclusions And Further Perspectives 3 4 5
- Developmental And Validation Studies
- Diagnostics
- Discussion
- Dpd Deficiency And Treatmentrelated Toxicities Upon 5fu Administration
- Drug Mechanism Of Action Probed By Pathway Gene Expressions And Growth Inhibition Response
- Egfr Function
- Estimates Of Predictive Accuracy In Developmental Studies
- Expression Studies
- FCGR3B Gene Polymorphism
- FU Analogs and Prodrugs
- Future Directions To Improve Efficacy Of Monoclonal Therapy
- Future Perspective
- Gene Approach
- Gene Expression
- Genetic Variations of UGT1A1 1A7 1A9 and 1A10
- Genotypic Approaches
- Ibritumomab Tiuxetan
- Induction of Apoptosis Antiproliferation
- Info
- Introduction - 2 3 4 5 6 7 8 9 10 11
- Irreversible Inhibitors of EGFR and Other ErbB Proteins
- Mapping Pathways to Drug Mechanism of Actions
- Market Segmentation
- Mass Spectrometry Analysis
- New Array Designs
- On Tumor Samples
- Other Strategies to Target EGFR function
- Overview Of Gene Expression Analyses
- Perspective
- Pharmacogenomic Biomarker Classifiers
- Phenotypic Approaches
- Polymorphism Of The Genes In The Complement Pathways And Clinical Data
- Primary And Acquired Resistance To Egfr Tkis
- Primary or De Novo Resistance to Egfr Tkis
- Prognostics
- Pros and Cons of the Pathway Based Approach
- Proteomics for HCC Tissues from Patients
- Reduced Folate Carrier Rfc Gene
- References
- Regulatory Status Of Irinotecan Therapy
- RFC Confounding Issues
- RFC Studies
- Rituximab And Its Mechanism Of Action
- Signal Amplification Post Hybridization
- Structural Insights into Hyperactivation ofEGFR Mutants
- Summary - 2 3 4 5 6 7 8 9 10 11 12 13
- T7Eberwine Type Amplification
- The Biochemical And Signaling Properties Of Egfr Mutants
- The Fc7 Receptor Gene Polymorphism And In Vitro Data
- The Molecular Basis for Sensitivity ofEGFR Mutants to Selective TKIs
- Thymidylate Synthase 31 UTR 6bp Deletion
- Thymidylate Synthase Confounding Issues
- Thymidylate Synthase Studies
- Tositumomab
- TSER 3R G to C Single Nucleotide Polymorphism SNP
- Tumor Microdissection
- Two Dimensional Gel Electrophoresis
- Use of Paraifin Embedded Material for SNP Array Analysis
- Use Of Pharmacogenomic Classifiers In New Drug Development
- Using Gene Expression
- Validation Of Snp Array Data
